drugset / Trial / NCT00668304

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

NCT00668304

Phase 4 Completed 192 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.

Timeline

Start
2004-06
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral

Indications